Functional imaging of neoadjuvant chemotherapy response in women with locally advanced breast cancer using diffuse optical spectroscopy

Author(s):  
H. Soliman ◽  
M.J. Yaffe ◽  
G.J. Czarnota
2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 3591-3591 ◽  
Author(s):  
H. Soliman ◽  
A. Gunasekara ◽  
M. Rycroft ◽  
J. Zubovits ◽  
R. Dent ◽  
...  

3591 Background: Functional imaging with tomographic near infrared diffuse optical spectroscopy (DOS) can quantitatively measure tissue parameters such as the concentration of deoxy-hemoglobin (Hb), oxy-hemoglobin (HbO2), percent water (%water), and scattering power (SP). The purpose of this study was to evaluate the correlation between DOS functional parameters with pathologic outcomes. Methods: Patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy or chemoradiotherapy were recruited to this study (n=10). Five scans were conducted per patient: a baseline scan taken up to 3 days prior to treatment and at 1 week, 4 weeks, 8 weeks, and after neoadjuvant treatment prior to surgery. Pulsed near-infrared laser light was used to scan the suspended breast at four different wavelengths and data was used for tomographic reconstruction. Volume-of-interest (VOI) weighted tissue Hb, HbO2, %water, and SP corresponding to the tumour was calculated and compared to pathological response as determined from full mount mastectomy specimens. Results: For all 10 patients the tumour-based VOI was significantly different than background tissue for all functional parameters (p<0.001). Five patients had a good pathologic response. Four patients were considered non-responders. One patient initially had a poor clinical response to chemotherapy but after a change in chemotherapy had a good clinical response. Responders and non-responders were significantly different for all of the functional parameters (p<0.05) at the 4 week scan. In the 5 patients with a good response the mean drop in Hb, HbO2, %water, and SP from baseline to the 4 week scan was 70.4% (SD=18.6), 66.5% (SD=24.5), 59.6% (SD=30.9), and 60.7% (SD=29.2), respectively. In contrast, the 4 non- responders had a mean drop of 17.7% (SD=9.8), 18.0% (SD=20.8), 15.4% (SD=11.7), and 12.6% (SD=10.2), for Hb, HbO2, %water and SP, respectively. Conclusions: Functional imaging using tomographic DOS parameters of Hb, HbO2, %water and SP could be used as an early detector of final pathologic tumour response. This could be evaluated in the future to assess response and potentially adjust chemotherapy regimens. No significant financial relationships to disclose.


2013 ◽  
Vol 6 (1) ◽  
pp. 17-24 ◽  
Author(s):  
Omar Falou ◽  
Ali Sadeghi-Naini ◽  
Sameera Prematilake ◽  
Ervis Sofroni ◽  
Naum Papanicolau ◽  
...  

2018 ◽  
Vol 1 (1) ◽  
pp. 1-9
Author(s):  
Ade Permana ◽  
Benny Kusuma ◽  
Nur Qodir ◽  
Legiran

Introduction. CD4+ T-helper has an important role in immune system modulation especially to maintain long-term anti tumor effect. CD4+ also serves to activate CD8+ for destroyed the tumor cells. It was expected there were role of immunity on tumor growth and response of breast cancer chemotherapy to CD4+ levels serum. Furthermore, this study was aimed to investigate the effects of neoadjuvant chemotherapy on CD4+ levels in patients with locally advanced breast cancer at General Hospital Dr. Mohammad Hoesin Palembang. Method. This study was a non-comparable clinical trial by looking at serum CD4+ levels in patients with locally advanced breast cancer before and after neoadjuvant chemotherapy.   Results. Of the 30 subjects the subject age ranged from 33-66 years with an average of 45 years. There were 17 patients with contraception history (56.7%), 13 patients with family history of breast cancer (43.3%). From this study, it was obtained 23 patients with good chemotherapy response (76.7%) and there were 7 patients who had poor chemotherapy response after neoadjuvan chemotherapy (23.3%). Paired t-test analysis showed that there was a significant difference in mean CD4+ count before and after neoadjuvan chemotherapy. At the CD4+ level before chemotherapy 775.55 had a sensitivity of 60% and a specificity of 57% (cut of point). While CD4+ levels after chemotherapy 470.85 with sensitivity of 60% and specificity of 57%.   Conclusion. CD4+ pre-chemotherapy examination had a sensitivity score of 60% and a specificity of 57% in predicting neoadjuvant chemotherapy response.    


Sign in / Sign up

Export Citation Format

Share Document